Health
Obesity Drug WeGovy to Drive Up Profits at Novo Nordisk
- Operating profit seen rising as much as 29% this year
- Danish drugmaker sees competition heating up, price pressures
Novo Nordisk A/S said sales and profit will surge again this year as it continues to roll out its blockbuster obesity shot Wegovy around the world.
Revenue could grow by as much as 26% and operating profit by up to 29% at constant exchange rates, the drugmaker said Wednesday.